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Background: Hypertrophic cardiomyopathy (HCM) is a genetic condition, and relatives of affected persons may be
at risk. Cardiac troponin biomarkers have previously been shown to be elevated in HCM. This study examines the
new highly-sensitive cardiac troponin I (hsTnI) assay in a HCM screening population.
Methods: Nested case–control study of consecutive HCM sufferers and their relatives recruited from May 2010 to
September 2011. After informed consent, participants provided venous blood samples and clinical and
echocardiographic features were recorded. Associations between the natural log (ln) of the contemporary troponin
I (cTnI) and hsTnI assays and markers of cardiac hypertrophy were examined. Multiple regression models were fitted
to examine the predictive ability of hsTnI for borderline or definite HCM.
Results: Of 107 patients, 24 had borderline and 19 had definite changes of HCM. Both TnI assays showed
significant, positive correlations with measures of cardiac muscle mass. After age and sex adjustment, the area
under the receiver operator characteristic (AUROC) curve for the outcome of HCM was 0.78, 95% CI [0.65, 0.90], for
ln(hsTnI), and 0.66, 95% CI [0.51, 0.82], for ln(cTnI) (p=0.11). Including the hsTnI assay in a multiple-adjusted
“screening” model for HCM resulted in a non-significant improvement in both the AUROC and integrated
discrimination index.
Conclusions: Both cTnI and hsTnI show a graded, positive association with measures of cardiac muscle mass in
persons at risk of HCM. Further studies will be required to evaluate the utility of these assays in ECG- and
symptom-based identification of HCM in at-risk families.
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Hypertrophic cardiomyopathy (HCM) is a genetic condition
with otherwise unexplained left ventricular hypertrophy in
the absence of LV chamber dilatation [1]. It is a relatively
common condition [2], and carries an increased risk of
arrhythmia and sudden cardiac death, even in those persons
with clinically “silent” or unrecognised HCM. Therefore,
cardiac screening of first-degree relatives of HCM probands
is now advised [3]. Cascade screening may be clinical with* Correspondence: catherine.mcgorrian@ucd.ie
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distribution, and reproduction in any mediuman electrocardiogram (ECG) and transthoracic echocardio-
gram (echo), genetic (if the family mutation is identified ),
or a combination of both. However, such screening presents
multiple challenges. For genetic evaluation, causative gene
identification is currently possible in 40-70% of tested
families [4]. In clinical evaluations, it can be a challenge
to differentiate between early HCM changes and other
findings such as the athlete’s heart [5] and hypertensive
heart disease [6].
Biomarkers are naturally occuring molecules which
may indicate a disease process. Cardiac troponins are
biomarkers which are released due to myocyte necrosis,
and cardiac troponin I (TnI) is specific to cardiac muscle.
There is a known association between cardiac troponintral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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sensitivity cardiac troponin I (hs cTnI) assays have become
available [10], and will ultimately replace contemporary
cTnI assays. Such hsTnI assays not only provide greater
precision at the 99th percentile limits, but can also detect
lower levels of troponin “leak” with greater sensitivity. It is
not known how hsTnI assays may behave in persons with
or at risk of HCM, but it may be that these lower
levels of cTnI may provide useful screening information in
such persons.
In this study, we aimed to examine the distribution of
TnI, measured with both a standard contemporary (cTnI)
and new highly-sensitive assay, in a high-risk population
for HCM. A “proof of concept” investigation was under-
taken to examine the association of cTnI and hsTnI with
echocardiographic markers of HCM, and the incremental
screening value of adding highly-sensitive biomarker data
to ECG and clinical data was assessed.
Methods
Study population
The Family Heart Screening Study is a prospective
single-centre cohort study of patients at risk of familial
cardiac conditions, based in a screening clinic for familial
cardiomyopathies and channelopathies. From March 2010
to August 2011, all patients attending for HCM screening
were considered for study inclusion. Patients were included
if they had a first or second degree relative with HCM, and
were aged 18 and over. Only patients who provided
informed consent for both data collection and serum
sampling were included in this analysis. Ethical approval
for this study was granted by the Mater Misericordiae
University Hospital Research Ethics Committee, and the
study was conducted with due regard to the principles of
the Declaration of Helsinki.
Patients underwent protocol-driven clinical screening,
with clinical history-taking and examination, pedigree ana-
lysis, and ECG and echo. Data were collected on baseline
symptoms including chest pain, dyspnoea, palpitations and
syncope. Patients were deemed to be symptomatic if they
described any of these symptoms. ECGs were defined as
abnormal if any typical “Group 2” ECG changes were noted
(i.e. presence of ST depression or T-wave inversion,
pathological Q waves, interventricular conduction de-
lays, deviations in cardiac axis, long or short QT and/or
Brugada-like repolarisation changes) [11]. Body surface
area (BSA) was calculated for all persons in whom weight
and height were available.
Echocardiograph measurements
Transthoracic echo studies were performed by a senior
echocardiographer using a commercially available system
(Vivid 7, GE Healthcare, Horten, Norway) with a 3.5-MHz
transducer. Images were obtained in standard views andwere digitally stored for offline analysis (Echopac Version
7.0., GE Healthcare). The ejection fraction (EF) was
calculated using Simpson’s rule [12]. Peak E and A
velocities, E/A ratio and deceleration time (DT) were
recorded using pulse wave (PW) Doppler in the apical
4-chamber view. Tissue Doppler PW analysis was also
used to measure mitral annular velocities, with the
sample volume at the septal and lateral annulus insertion
of the mitral valve leaflets (septal and lateral S’, E’ and A’).
Left ventricular mass (LV mass) was calculated using the
American Society of Echocardiography (ASE) method
[13]. All echo images were read offline by two observers
blinded to patient history.
The interventricular septum diameter in diastole (IVSd)
and left ventricular posterior wall diameter in diastole
(LVPWd) were used to calculate the IVSd/LVPWd ratio.
The relative wall thickness (RWT) was calculated by
dividing the IVSd/LVPWd ratio by the left ventricular
end-diastolic diameter (LVEDD) [12]. The maximal wall
thickness (MWT) was calculated from the parasternal
short-axis view in 2D Mode by taking the maximal thick-
ness of the left ventricular wall in end diastole in any of the
following segments: anterior septum, posterior septum, pos-
terolateral wall and anterolateral wall. The Maron-Spirito
index was calculated by taking the sum of the left ventricu-
lar (LV) maximal thickness at each of these segments,
measured both at basal (mitral valve) and mid ven-
tricular (papillary muscle) levels [14]. The “adjusted
2D-LVH”scale was calculated as described by Forissier et al.,
where 2D LVH score= 18.95+ (0.12*age in years) +
(2.64*male sex) + (6.41*BSA in kg/m2) [15]. The echo- and
tissue doppler-based risk score of Gandjbakhch et al.
for HCM mutation carrier probability was calculated
using the equation p = −19.1861 + (6.195 ×IVS/LPW) +
(22.538 × RWT) + (0.5613 × septal E/Ea) [16].
Biomarker analyses
A single lithium-heparin venous sample (8ml) was drawn
and transferred to a refrigerator at 4°C. The samples were
centrifuged within 4 hours of collection, and the plasma
sample was assigned a unique identifier number and frozen
directly at −80°C. The hsTnI analysis was performed using
the ARCHITECT STAT High Sensitive Troponin I assay
on the ARCHITECT i1000SR system (Abbott Diagnostics).
The concentration of the hsTnI was read relative to a
standard curve derived with calibrators of known hsTnI
concentration. The cTnI analysis was performed on
samples which had undergone a single previous thaw,
with an ARCHITECT STAT Troponin-I assay, also
on the ARCHITECT i1000SR system. The concentra-
tion of the cTnI present was read relative to a stand-
ard curve derived with calibrators of known cTnI
concentration. Standard procedures were followed for
callibration and norms.
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relatives (with a normal cardiovascular examination, ECG
and echo) served to define the 99th centile for the normal
population (in this study, 24.88 pg/ml). In healthy individ-
uals, values of troponin (Tn) are low and many fall below
the detection limit of contemporary assays. Therefore the
99th centile of the healthy population is recommended as
a clinical decision cut off value. For the contemporary
cTnI assay, the assay precision is ≤10% total coefficient of
variation (CV) for samples ≥ 0.2 ng/mL with an ana-
lytical sensitivity of ≤ 0.01 ng/mL at the 95% confi-
dence interval (CI). The hsTnI assay has a 10% CV at
0.047 ng/ml with a limit of detection ≤0.002 ng/ml.
The analytical specificity is ≤0.1% cross-reactivity with
skeletal troponin-I and ≤ 1% with cardiac troponin-T
and troponin-C.Statistical analysis
Patient outcomes were defined using established echo
criteria for HCM (1,3). Patients with a MWT <13 mm
were deemed to have no evidence of HCM, with patients
with a MWT of ≥15 mm deemed to have a definite find-
ing of HCM. Patients with a MWT of 13-14 mm were
deemed to have borderline changes. Descriptive statistics
were used to describe the clinical and echo characteristics
of the screened population by screening outcome, using
contingency tables and the Pearson chi-square test to
compare categorical variables and simple analysis of vari-
ance models (ANOVA) to compare continuous variables
between the three groups. The distribution of the
cTnI and hs cTnI biomarkers in the populations wereTable 1 Baseline characteristics of the study population, strat
Total (n = 107) Normal scre
echo (n
Demographic data
Age in years: mean [SD] 39.30 (13.86) 35.63 [
Male sex: n (%) 63 (58002E9%) 32 (5
BMI in kg/m2: mean [SD] 26.94 (3.90) 25.67
Relationship to the family proband
Proband: n (%) 8 (7.5%) 0
1st degree relative : n (%) 82 (76.6%) 53 (8
2nd degree or higher : n (%) 17 (15.9%) 11 (1
Clinical History
Any symptoms: n (%) 36 (33.6%) 18 (2
Chest pain: n (%) 10 (9.4%) 7 (1
Dyspnoea: n(%) 12 (11.2%) 5
Palpitations: n(%) 17 (15.9%) 7 (1
History of syncope: n(%) 6 (5.6%) 2
BMI Body Mass Index.examined, and a natural log transformation was used
to allow the use of parametric statistics.
Pearson’s correlation coefficient was used to examine
correlations between the biomarker measures and key
echo measurements, and two way scatterplots with fitted
ordinary least-squares regression lines were used.
Analysis of the biomarkers proceded as suggested by
Hlatky et al. [17]. Simple logistic regression models
were fitted, adjusting for age and sex, with either
cTnI or hsTnI as the independent variable, and the
presence of an abnormal echo screening evaluation as
the dependent variable. Area under the receiver operator
characteristic (AUROC) curve was calculated and
compared for the logistic models described [18]. To
examine the potential utility of the biomarker in a
clinic or screening context, three forward stepped logistic
models were fitted, with the a possible or definite HCM
finding on echo as the dependent variable. The first
“simple” model had age, sex and symptoms (any of
chest pain, dyspnoea, palpitations and syncope) as inde-
pendent variables; the second “clinic model” then included
abnormal or “group 2” ECG findings [11]; and the third
“enhanced” model included ln(hsTnI). Measurement of
the model r2, AUROC, and integrated discrimination index
(IDI) was undertaken [19]. All analyses were performed
with Intercooled Stata 11 (StataCorp™, Texas).Results
Complete clinical data were available on 107 patients who
underwent screening for HCM. The baseline population







12.26] 44.92 [12.793] 44.59 [16.63] F=6.15, p=0.003
0.0%) 20 (83.3%) 11 (57.9%) Χ2=8.01, p=0.018
(3.90) 29.08 [3.88] 27.70 [3.07] F=5.97, p=0.004
(0%) 1 (4.2%) 7 (36.85%) Fishers exact p<0.005
2.8%) 20 (83.3%) 9 (47.4%)
7.2%) 3 (12.5%) 3 (15.8%)
8.1%) 8 (33.3%) 10 (52.5%) Χ2=3.94, p=0.139
0.9%) 2 (8.3%) 1 (5.3%)
(7.8%) 3 (12.5%) 4 (21.1%) Fishers exact p=0.267
0.9%) 4 (16.7%) 6 (31.6%) Fishers exact p=0.089
(3.1%) 2 (8.3%) 2 (10.5%) Fishers exact p=0.286
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referred for assessment to confirm the HCM diagnosis. Of
these probands, seven had definite and one had borderline
HCM changes on echo. Table 2 describes the echo charac-
teristics in this population. As might be expected by the
echo-based stratificication method used, echo markers ofTable 2 Echocardiographic characteristics of the study popula
Normal screening
echo (n = 64)
B
2D-TM Data: mean [SD]
IVSd (mm) 10.30 (2.17)
LVPWd (mm) 9.22 (1.67)
IVS/LVPW ratio 1.13 (0.20)
LVIDd (mm) 48.86 (5.76)
LA diameter (mm) 34.75 (5.62)
LVEF M Mode (%) 61.81 (7.08)
LVOT gradient (mmHg) 5.32 (1.87)
RWT (mm) 0.38 (0.06)
MWT (mm) 10.62 (1.13)
Maximal LV wall dimensions in diastole:
Antero- septal wall (mm) 10.12 (1.37)
Postero- septal wall (mm) 9.88 (1.32)
Antero-lateral wall (mm) 9.22 (1.13)
Posterior wall (mm) 9.25 (1.09)
LV Mass (g) 172.55 (48.34)
Pulsed Doppler
Peak E velocity (cm/s) 0.80 (0.17)
Peak A velocity (cm/s) 0.58 (0.17)
E/A ratio 1.49 (0.49)
E deceleration time (ms) 187.87 (60.29)
Tissue Doppler
Septal Sa (cm/s) 8.25 (2.35)
Septal Ea (cm/s) 10.22 (3.33)
Septal Aa (cm/s) 8.89 (2.11)
Lateral Sa (cm/s) 10.13 (3.38)
Lateral Ea (cm/s) 12.87 (5.99)
Lateral Aa (cm/s) 8.85 (2.99)
Echocardiograph composite scores
Adjusted 2D-LVH score 36.28 (2.69)
Spirito index (mm) 38.47 (3.71)
Gandjbakhch risk score −2.78 (1.59)
* Comparisons across the strata of echo findings were made using ANOVA.
IVSd Interventricular septum diameter in diastole.
LVPWd Left ventricular posterior wall diameter in diastole.
LVIDd Left ventricular internal diameter in diastole.
LA Left atrium.
LVEF Left ventricular ejection fraction.
LVOT Left ventricular outflow tract.
RWT Relative wall thickness.
MWT Maximal wall thickness.increased left ventricular thickness and reduced diastolic
function, as well as three echo-based scores of left
ventricular hypertrophy and HCM [14-16], were observed
to increase by diagnostic stratum.
The results of the cardiac troponin assays are shown






12.38 (2.36) 15.53 (4.50) F= 27.33 <0.0001
11.00 (2.57) 11.32 (2.31) F=11.79 <0.0001
1.17 (0.33) 1.38 (0.33) F=6.77 0.0017
50.42 (6.00) 47.16 (7.92) F= 1.45 0.239
38.98 (4.02) 36.72 (4.96) F= 5.73 0.0044
66.17 (7.46) 68.33 (11.82) F=5.67 0.0046
5.91 (2.39) 7.00 (3.27) F=3.35 0.0399
0.44 (0.07) 0.50 (0.08) F=26.78 <0.0001
13.42 (0.50) 17.63 (3.65) F= 118.46 <0.0001
12.58 (1.10) 16.63 (3.39) F=93.87 <0.0001
12.67 (1.27) 15.84 (4.57) F=55.64 <0.0001
10.83 (1.61) 11.53 (2.09) F=23.74 <0.0001
10.96 (1.08) 11.68 (2.03) F=32.74 <0.0001
230.29 (60.66) 268.53 (133.37) F=14.96 <0.0001
0.73 (0.22) 0.79 (0.14) F=1.60 0.206
0.58 (0.13) 0.60 (0.18) F=0.16 0.854
1.31 (0.51) 1.45 (0.61) F=0.98 0.379
203.50 (33.91) 220.11 (61.30) F=2.60 0.079
7.68 (2.48) 7.10 (1.99) F=1.54 0.220
7.01 (3.29) 7.90 (3.90) F=8.02 0.0006
8.96 (3.58) 8.09 (2.64) F=0.60 0.550
8.41 (3.14) 8.29 (2.44) F=3.18 0.047
9.95 (4.03) 11.19 (4.27) F=2.52 0.087
7.87 (3.39) 7.78 (3.50) F=1.06 0.350
39.71 (2.69) 39.03 (2.80) F=12.33 <0.0001
47.04 (3.03) 55.68 (9.53) F=90.81 <0.0001
−0.95(3.77) 0.57 (2.59) F=11.91 <0.0001
Table 3 Description of the cardiac troponin and highly sensitive troponin findings in the screening population
Normal screening echo Borderline HCM Definite HCM Test statistic; P-value
Sample size: 56 20 17
Cardiac Troponin I Log cTnI: mean(SD) −4.71 (0.01) −4.60 (0.34) −4.31 (0.94) F= 5.63; p= 0.005
Abnormal cTnI: n(%) 0 (0%) 1 (5%) 3 (18.8%) Fisher’s exact p= 0.006
Sample size: 63 22 19
High-sensitivity cardiac troponin I Log hsTnI: mean (SD) 0.62 (1.08) 1.34 (1.00) 1.94 (1.45) F=11.06; p<0.0001
Abnormal hsTnI: n(%) 1 (1.6%) 1 (4.6%) 4 (22.2%) Fisher’s exact p=0.008
HCM Hypertrophic cardiomyopathy.
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assay. Significant increases in TnI both by the contem-
porary and highly-sensitive assay were seen across the
HCM strata. This graded association was also seen when
99th percentile cut points were applied. A box plot
displaying this significant increase in ln(hsTnI) is shown
in Figure 1. This relationship between both cTnI and
hsTnI and echo-based measures of LV hypertrophy and
diastolic function was examined further using Pearson’s
correlation coefficient, and strong, positive relationship
were again noted between the measures of LV hypertrophy
and TnI (Additional file 1: Table S1).
Figure 2 shows the association between the natural log
of hsTnI and key measures of LV mass (MWT, IVS:
LVPWd ratio, LV mass and the Spirito score). Ordinary
least-squares regression lines were fitted, with adjusted R2
values of up to 0.29 for the model with the Spirito score
as the dependent variable. Simple and multiple-adjustedFigure 1 Box plot of the natural log of highly-sensitive cardiac tropon
Footnote for Figure 1: p values shown are from the Wilcoxon rank sum tes
Borderline change groups: z=−2.47, p=0.013. For the the difference in ln(hs
z=−1.59, p=0.112. For the the difference in ln(hsTnI) between the Definite Hlogistic models for possible or definite HCM by echo
criteria [1,3] are shown in Table 4. For both models,
the odds ratio associated with hsTnI, but not cTnI,
was statistically significant. Furthermore, the models
which included hsTnI had non-significant increases in
AUROC when compared with equivalent models with
the cTnI assay as a covariable.
We examined the potential screening utility of the
hsTnI assay in a screening setting for HCM. Table 5
shows incremental though statistically non-significant
gains in model R2and AUROC when the hsTnI assay
was added to the “screening” model, and there was a
trend towards an improvement in IDI with the “enhanced
screening” model when compared to the model without ln
(hsTnI). The sensitivity of the ln(hsTnI) “enhanced
screening” model was 53.7% and specificity was 88.9%,
with a positive predictive value of 75.9% and a negative
predictive value of 74.7%.in I by HCM groups as stratified by standard echo criteria.
t. For the the difference in ln(hsTnI) between the no HCM and
TnI) between the Definite HCM and Borderline change groups:
CM and no HCM groups: z=−3.468, p=0.0005.
Figure 2 Scatterplot with fitted linear regression line, showing the association between the natural log of highly sensitive
cardiac troonin I with a. the IVS:LVPW ratio, b. the MWT, c. the LV mass estimate and d. the Spirito index. Footnote for Figure 2:
Regression coefficient for the IVSd: LVPWd ratio was 0.008, 95% CI [0.52, 2.19], p=0.002, adjusted R2 0.08. Regression coefficient for the LV
maximal wall thickness was 0.20, 95% CI [0.13, 0.26], p<0.0005, adjusted R2 0.25. Regression coefficient for the LV mass was 0.088, 95%
CI [0.005, 0.010], p<0.0005, adjusted R2 0.26. Regression coefficient for the Spirito score was 0.08, 95% CI [0.06, 0.10], p<0.0005,
adjusted R2 0.29.
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Description of key findings
This study aimed to examine the association between
cardiac troponin I and the clinical diagnosis of hyper-
trophic cardiomyopathy in a high-risk screening
population, with a focus on the new highly-sensitive
cTnI assay method. There was a clear and consistent
graded association between cTnI (measured both by
the contemporary and highly-sensitive assays) and
measures of LV hypertrophy, whereas the association
of the troponin measurements with functional mea-
sures such as diastolic function were less clear. While
improvements in IDI and AUROC were noted when
the hsTnI assay measure was added to a clinic-based
regression model to predict the finding of an echoTable 4 Association of both standard and highly sensitive car
HCM, using logistic regression analysis
Odds ratio (95% CI)
cTnI models
Model 1* Natural log of cTnI 4.20 (0.94, 18.80)
Model 2 ** 2.56 (0.54, 12.14)
hsTnI models
Model 1* Natural log of hsTnI 2.35 (1.39, 3.96)
Model 2 ** 1.82 (1.02, 3.24)
* Model 1 adjusted for age and sex.
** Model 2 adjusted for age, sex, presence of group 2 ECG abnormalities, and symp
Footnote: For the ln(cTnI): comparison between AUROC in Model 1 vs Model 2: χ2=
Model 2: χ2=1.03, p=0.310. For the comparison between the AUROCs in Model 2 fofinding consistent with a clinical diagnosis of border-
line or definite HCM, these improvements were not
statistically significant.
Where this fits in the literature
There is emerging interest in the possibility of using
highly-sensitive troponin measures in risk stratification
in cardiovascular diseases. Highly-sensitive troponin I
has been shown to contribute to athersclerotic CVD and
heart failure risk in primary prevention populations,
even after adjustment for multiple traditional risk factors
[20,21]. However, it is not clear why troponins I and T
may be elevated in HCM. Current theories include
the concept that the elevation may be due to myocyte
necrosis from a mismatch between the hypertrophieddiac troponin I assays with an echo diagnosis of definite
P value Pseudo R2 AUROC (95% CI)
0.060 0.102 0.66 (0.51, 0.82)
0.236 0.197 0.76 (0.62, 0.91)
0.001 0.173 0.78 (0.65, 0.90)
0.042 0.231 0.81 (0.70, 0.93)
toms of dyspnoea, chest pain, syncope or palpitations.
1.90, p=0.168. For the ln(hsTnI): comparison between AUROC in Model 1 vs
r the models with ln(cTnI) and ln(hsTnI): χ2= 0.87, p=0.351.
Table 5 HCM screening and the effect of the addition of the troponin measures screening models, using logistic
regression with boderline or definite HCM findings at echo as the dependent variable
Model Covariables n Pseudo R2 AUROC (95% CI)
Simple model Age, sex and symptoms 104 0.177 0.75 (0.65, 0.86)
Screening model Age, sex, symptoms and “Group 2” ECG changes 104 0.189 0.77 (0.67, 0.87)
Enhanced screening model with cTnI Age, sex, symptoms, “Group 2” ECG changes and ln(cTnI) 104 0.201 0.75 (0.63, 0.86)
Enhanced screening model with hsTnI Age, sex, symptoms, “Group 2” ECG changes and ln(hsTnI) 104 0.225 0.78 (0.69, 0.88)
Footnote: Integrated discrimination index (IDI) for the addition of the ln(cTnI) to the “Screening” model is 0.025 (standard error 0.024), p=0.299. Integrated
discrimination index (IDI) for the addition of the ln(hsTnI) to the “Screening” model is 0.036 (standard error 0.019), p=0.056.
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or that the elevation is caused by the underlying genetic
abnormality [22].
Cardiac troponin assays have been previously es-
tablished to be associated with degree of hypertrophy in
patients with known HCM [23]. CTnI is correlated with
maximal LV wall thickness in patients with hypertrophic
cardiomyopathy [8]. Moreno et al. described an out-
patient population with HCM, in who 42% had an ele-
vated hsTnT level, and patients with higher hsTnT
levels were more likely to have symptoms of dyspnoea
and/or fibrosis on cardiac MRI evaluation [9]. It has also
been reported to be elevated in HCM caused by Fabry’s
disease [24]. Cardiac troponin I has also been linked to
outcome status in HCM, with a combination of cTnI
and BNP predicting adverse cardiovascular outcomes
[25]. However, the utility of cTnI and hsTnI in a
HCM screening population has not previously been
evaluated. Furthermore, we are not aware of any pre-
vious study which has compared the relative utility of
the two assay types in such a population.
Strengths and limitations
This study reports the first examination of a new
highly sensitive TnI assay in patients both with, and
at risk of, HCM. Furthermore, our analysis presents a
novel potential use for cTnI and hsTnI, using a high-
risk screening population for HCM. The population
was well phenotyped, with echos read independently
and in a blinded manner. Our study has some limita-
tions. The data described are cross-sectional data, and
clinical outcome data are not yet available. A cohort
study on this population is ongoing. Other authors
have used an analysis endpoint of HCM genotype status.
This was not consistently available for our patients, and
we note that HCM genotype may not be available in many
clinical situations where a rapid decision on risk status is
required. An echocardiographic end-point has good
face validity and a well-established clinical application.
Tissue and pulsed Doppler measures of diastolic dysfunc-
tion were used in this study, and were seen not to have a
consistent relationship with cTnI or hsTnI. Use of a
further robust measure such as speckle-trackingechocardiography should however be considered for
future studies. The sample size was small, and there-
fore this study aimed to establish “proof of concept”
only [17]. Whilst small improvements in “clinic”
stratification were seen using hsTnI, these were not
statistically significant. Further study recruitment is
underway. The study sample are from a high-risk
screening population, and it is not known how hsTnI
may add to HCM diagnosis in population-screening
samples.Implications for practice
This study shows a potential role for cardiac troponin
assays, in particular assays of hsTnI, in HCM screening.
This finding needs to be replicated in other studies and
also ideally examined in a prospective cohort setting.
We examined a “high-risk” screening population for
HCM. Population screening for inherited cardiac dis-
eases is a topic of much debate, and there is particu-
lar focus on screening young athletes, in whom both
a questionnaire and ECG are recommended [26].
However, identification of HCM and risk stratification
can be clinically challenging. Furthermore, in young
patients and sportspersons in particular, the ramifications
of a HCM diagnosis can be substantial [27]. Highly-
sensitive troponin assays are relatively inexpensive, and
will be widely available in the future. This study provides a
rationale for further investigation of the utility of this
measure in the identification and management of patients
with HCM.Conclusions
This is the first study to examine a new hsTnI assay
in persons at risk of HCM. Both cTnI and hsTnI are
shown to have a graded, positive association with
measures of muscle mass in persons with and at risk
of HCM. There was a non-significant increase in AUROC
with the addition of hsTnI to the clinic “screening” model.
The cTnI and new hsTnI assay may add to ECG- and
symptom-based identification of HCM in at-risk families,
although further larger scale studies will be required to
evaluate this.
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